NASDAQ:CASI

CASI Pharmaceuticals Competitors

$2.18

-0.21 (-8.79 %)

(As of 03/4/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.10

Now: $2.18▼

$2.42

50-Day Range

$2.39

MA: $3.11▼

$3.63

52-Week Range

$1.15

Now: $2.18▼

$3.90

Volume353,279 shs

Average Volume503,281 shs

Market Capitalization$270.20 million

P/E RatioN/A

Dividend YieldN/A

Beta0.41

CASI Pharmaceuticals (NASDAQ:CASI) Vs. MESO, CRTX, ADVM, INBX, AERI, and PASG

Should you be buying CASI stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to CASI Pharmaceuticals, including Mesoblast (MESO), Cortexyme (CRTX), Adverum Biotechnologies (ADVM), Inhibrx (INBX), Aerie Pharmaceuticals (AERI), and Passage Bio (PASG).

CASI Pharmaceuticals vs. Mesoblast Stock

Mesoblast (NASDAQ:MESO) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, analyst recommendations, dividends, risk, institutional ownership, profitability and valuation.

Valuation and Earnings

This table compares Mesoblast and CASI Pharmaceuticals' revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$32.16 million	33.54	$-77,940,000.00	($0.74)	-12.41
CASI Pharmaceuticals	$4.13 million	65.42	$-46,030,000.00	($0.42)	-5.19

CASI Pharmaceuticals has lower revenue, but higher earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current recommendations for Mesoblast and CASI Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1	3	2	0	2.17
CASI Pharmaceuticals	0	0	2	0	3.00

Mesoblast presently has a consensus price target of $14.55, indicating a potential upside of 58.50%. CASI Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 94.95%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Mesoblast.

Profitability

This table compares Mesoblast and CASI Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mesoblast	-591.00%	-18.69%	-13.85%
CASI Pharmaceuticals	-402.87%	-60.96%	-42.48%

Insider and Institutional Ownership

2.8% of Mesoblast shares are owned by institutional investors. Comparatively, 32.0% of CASI Pharmaceuticals shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 24.8% of CASI Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk & Volatility

Mesoblast has a beta of 3.71, indicating that its share price is 271% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.

Summary

CASI Pharmaceuticals beats Mesoblast on 9 of the 13 factors compared between the two stocks.

CASI Pharmaceuticals vs. Cortexyme Stock

CASI Pharmaceuticals (NASDAQ:CASI) and Cortexyme (NASDAQ:CRTX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares CASI Pharmaceuticals and Cortexyme's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$4.13 million	65.42	$-46,030,000.00	($0.42)	-5.19
Cortexyme	N/A	N/A	$-36,980,000.00	($1.94)	-18.75

Cortexyme has lower revenue, but higher earnings than CASI Pharmaceuticals. Cortexyme is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for CASI Pharmaceuticals and Cortexyme, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0	0	2	0	3.00
Cortexyme	2	1	4	0	2.29

CASI Pharmaceuticals currently has a consensus price target of $4.25, suggesting a potential upside of 94.95%. Cortexyme has a consensus price target of $50.00, suggesting a potential upside of 37.48%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe CASI Pharmaceuticals is more favorable than Cortexyme.

Insider and Institutional Ownership

32.0% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 55.5% of Cortexyme shares are held by institutional investors. 24.8% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 19.8% of Cortexyme shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares CASI Pharmaceuticals and Cortexyme's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-402.87%	-60.96%	-42.48%
Cortexyme	N/A	-37.78%	-35.24%

Volatility and Risk

CASI Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500. Comparatively, Cortexyme has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Summary

Cortexyme beats CASI Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

CASI Pharmaceuticals vs. Adverum Biotechnologies Stock

Adverum Biotechnologies (NASDAQ:ADVM) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Earnings and Valuation

This table compares Adverum Biotechnologies and CASI Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adverum Biotechnologies	$250,000.00	4,287.38	$-64,490,000.00	($1.01)	-10.85
CASI Pharmaceuticals	$4.13 million	65.42	$-46,030,000.00	($0.42)	-5.19

CASI Pharmaceuticals has higher revenue and earnings than Adverum Biotechnologies. Adverum Biotechnologies is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Adverum Biotechnologies and CASI Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adverum Biotechnologies	0	2	8	0	2.80
CASI Pharmaceuticals	0	0	2	0	3.00

Adverum Biotechnologies currently has a consensus target price of $23.50, suggesting a potential upside of 114.42%. CASI Pharmaceuticals has a consensus target price of $4.25, suggesting a potential upside of 94.95%. Given Adverum Biotechnologies' higher possible upside, equities analysts clearly believe Adverum Biotechnologies is more favorable than CASI Pharmaceuticals.

Profitability

This table compares Adverum Biotechnologies and CASI Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adverum Biotechnologies	N/A	-32.23%	-28.02%
CASI Pharmaceuticals	-402.87%	-60.96%	-42.48%

Institutional & Insider Ownership

97.4% of Adverum Biotechnologies shares are held by institutional investors. Comparatively, 32.0% of CASI Pharmaceuticals shares are held by institutional investors. 12.4% of Adverum Biotechnologies shares are held by company insiders. Comparatively, 24.8% of CASI Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Adverum Biotechnologies has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, CASI Pharmaceuticals has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Summary

Adverum Biotechnologies beats CASI Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

CASI Pharmaceuticals vs. Inhibrx Stock

CASI Pharmaceuticals (NASDAQ:CASI) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, institutional ownership, earnings, dividends, valuation, analyst recommendations and profitability.

Insider and Institutional Ownership

32.0% of CASI Pharmaceuticals shares are owned by institutional investors. Comparatively, 36.6% of Inhibrx shares are owned by institutional investors. 24.8% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for CASI Pharmaceuticals and Inhibrx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0	0	2	0	3.00
Inhibrx	0	0	4	0	3.00

CASI Pharmaceuticals presently has a consensus target price of $4.25, suggesting a potential upside of 94.95%. Inhibrx has a consensus target price of $34.6667, suggesting a potential upside of 30.52%. Given CASI Pharmaceuticals' higher probable upside, research analysts plainly believe CASI Pharmaceuticals is more favorable than Inhibrx.

Valuation and Earnings

This table compares CASI Pharmaceuticals and Inhibrx's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$4.13 million	65.42	$-46,030,000.00	($0.42)	-5.19
Inhibrx	N/A	N/A	N/A	N/A	N/A

Inhibrx has lower revenue, but higher earnings than CASI Pharmaceuticals.

Profitability

This table compares CASI Pharmaceuticals and Inhibrx's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-402.87%	-60.96%	-42.48%
Inhibrx	N/A	N/A	N/A

Summary

Inhibrx beats CASI Pharmaceuticals on 5 of the 8 factors compared between the two stocks.

CASI Pharmaceuticals vs. Aerie Pharmaceuticals Stock

CASI Pharmaceuticals (NASDAQ:CASI) and Aerie Pharmaceuticals (NASDAQ:AERI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Analyst Recommendations

This is a breakdown of current ratings and target prices for CASI Pharmaceuticals and Aerie Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CASI Pharmaceuticals	0	0	2	0	3.00
Aerie Pharmaceuticals	1	1	9	0	2.73

CASI Pharmaceuticals presently has a consensus target price of $4.25, indicating a potential upside of 94.95%. Aerie Pharmaceuticals has a consensus target price of $25.50, indicating a potential upside of 32.47%. Given CASI Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CASI Pharmaceuticals is more favorable than Aerie Pharmaceuticals.

Valuation and Earnings

This table compares CASI Pharmaceuticals and Aerie Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CASI Pharmaceuticals	$4.13 million	65.42	$-46,030,000.00	($0.42)	-5.19
Aerie Pharmaceuticals	$69.89 million	12.92	$-199,580,000.00	($3.40)	-5.66

CASI Pharmaceuticals has higher earnings, but lower revenue than Aerie Pharmaceuticals. Aerie Pharmaceuticals is trading at a lower price-to-earnings ratio than CASI Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

32.0% of CASI Pharmaceuticals shares are held by institutional investors. Comparatively, 99.9% of Aerie Pharmaceuticals shares are held by institutional investors. 24.8% of CASI Pharmaceuticals shares are held by company insiders. Comparatively, 9.7% of Aerie Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

CASI Pharmaceuticals has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Comparatively, Aerie Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Profitability

This table compares CASI Pharmaceuticals and Aerie Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CASI Pharmaceuticals	-402.87%	-60.96%	-42.48%
Aerie Pharmaceuticals	-231.05%	-135.57%	-37.23%

CASI Pharmaceuticals vs. Passage Bio Stock

Passage Bio (NASDAQ:PASG) and CASI Pharmaceuticals (NASDAQ:CASI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

67.6% of Passage Bio shares are owned by institutional investors. Comparatively, 32.0% of CASI Pharmaceuticals shares are owned by institutional investors. 24.8% of CASI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Passage Bio and CASI Pharmaceuticals' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Passage Bio	N/A	N/A	N/A
CASI Pharmaceuticals	-402.87%	-60.96%	-42.48%

Earnings and Valuation

This table compares Passage Bio and CASI Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Passage Bio	N/A	N/A	N/A	N/A	N/A
CASI Pharmaceuticals	$4.13 million	65.42	$-46,030,000.00	($0.42)	-5.19

Passage Bio has higher earnings, but lower revenue than CASI Pharmaceuticals.

Analyst Ratings

This is a summary of current ratings and target prices for Passage Bio and CASI Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Passage Bio	0	2	6	0	2.75
CASI Pharmaceuticals	0	0	2	0	3.00

Passage Bio presently has a consensus price target of $25.5297, indicating a potential upside of 31.39%. CASI Pharmaceuticals has a consensus price target of $4.25, indicating a potential upside of 94.95%. Given CASI Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CASI Pharmaceuticals is more favorable than Passage Bio.

Summary

Passage Bio beats CASI Pharmaceuticals on 5 of the 9 factors compared between the two stocks.